Country

Clinical trials in Australia

Active obesity and GLP-1 studies with at least one location in Australia.

75active studies

54recruiting now

33countries represented

838largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Metabolic Dysfunction-Associated Steatotic Liver DiseaseCondition

Tirzepatide, RetatrutideTreatment

Argentina, Australia563 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07165028See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Belgium187 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07392190See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

Peripheral Arterial DiseaseCondition

Orforglipron, PlaceboTreatment

Argentina, Australia161 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07223593See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Sleep Apnea, Obstructive, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Brazil115 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07369011See eligibility →

Recruiting nowPhase 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Obesity, OverweightCondition

Macupatide, EloralintideTreatment

Argentina, Australia42 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07215559See eligibility →

Recruiting nowPhase 3

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

Obesity, Weight GainCondition

Tirzepatide, PlaceboTreatment

Argentina, Australia69 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06439277See eligibility →

Recruiting nowPhase 3

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Atherosclerotic Cardiovascular Disease, OverweightCondition

Maridebart Cafraglutide, PlaceboTreatment

Argentina, Australia783 locations

AmgenSponsor

Updated 2026-09-03 · NCT07037433See eligibility →

Recruiting nowPhase 3

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Metabolic Dysfunction Associated SteatohepatitisCondition

Survodutide, Placebo matching survodutideTreatment

Argentina, Australia445 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT06632457See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Obesity With Diabetes, Overweight With DiabetesCondition

Ribupatide, PlaceboTreatment

Argentina, Australia167 locations

KaileraSponsor

Updated 2026-09-03 · NCT07284901See eligibility →

Recruiting nowPhase 3

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

Type 2 DiabetesCondition

Placebo, SurvodutideTreatment

Australia, Canada121 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07754461See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Obesity, OverweightCondition

Ribupatide, PlaceboTreatment

Argentina, Australia104 locations

KaileraSponsor

Updated 2026-09-03 · NCT07284875See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Obesity, OverweightCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Japan87 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684235See eligibility →

Recruiting nowPhase 2

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

Obesity, OverweightCondition

BI 3034701, Placebo matching BI 3034701Treatment

Australia, Canada54 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07662122See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

ObesityCondition

Ribupatide, SemaglutideTreatment

Australia, Bulgaria59 locations

KaileraSponsor

Updated 2026-09-01 · NCT07284979See eligibility →

Recruiting nowPhase 3

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

Obesity, Type 2 DiabetesCondition

Cagrisema, SemaglutideTreatment

Argentina, Australia303 locations

Novo Nordisk A/SSponsor

Updated 2026-08-31 · NCT07564414See eligibility →

Recruiting nowPhase 3

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Overweight, ObesityCondition

Cagrilintide, SemaglutideTreatment

Australia, Austria121 locations

Novo Nordisk A/SSponsor

Updated 2026-08-31 · NCT07253285See eligibility →

Recruiting nowPhase 3

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

ObesityCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Argentina, Australia72 locations

Novo Nordisk A/SSponsor

Updated 2026-08-27 · NCT07503210See eligibility →

Recruiting nowPhase 3

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

Obesity or OverweightCondition

AZD6234, PlaceboTreatment

Argentina, Australia212 locations

AstraZenecaSponsor

Updated 2026-08-25 · NCT07784725See eligibility →

Recruiting nowPhase 3

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver FibrosisCondition

Survodutide, PlaceboTreatment

Argentina, Australia528 locations

Boehringer IngelheimSponsor

Updated 2026-08-21 · NCT06632444See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Obesity, OverweightCondition

Eloralintide, PlaceboTreatment

Argentina, Australia162 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT07321886See eligibility →

Recruiting nowPhase 3

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

Obesity, Heart FailureCondition

NNC0487-0111, PlaceboTreatment

Argentina, Australia838 locations

Novo Nordisk A/SSponsor

Updated 2026-08-18 · NCT07567001See eligibility →

Recruiting nowPhase 1, Phase 2

A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

ObesityCondition

ARO-INHBE, PlaceboTreatment

Australia, New Zealand7 locations

Arrowhead PharmaceuticalsSponsor

Updated 2026-08-18 · NCT06700538See eligibility →

Recruiting nowPhase 3

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, Bulgaria81 locations

Novo Nordisk A/SSponsor

Updated 2026-08-17 · NCT07509307See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

Obesity or OverweightCondition

Placebo, EnicepatideTreatment

Argentina, Australia195 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351045See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity or Overweight, Type 2 Diabetes MellitusCondition

Placebo, EnicepatideTreatment

Argentina, Australia193 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351058See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil57 locations

AmgenSponsor

Updated 2026-08-14 · NCT07226765See eligibility →

Recruiting nowPhase 1

A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight

Obesity, OverweightCondition

VRB-103, PlaceboTreatment

Australia1 locations

Verdiva Bio Dev LimitedSponsor

Updated 2026-08-11 · NCT07628127See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

UBT251, UBT251 PlaceboTreatment

Australia, Germany70 locations

Novo Nordisk A/SSponsor

Updated 2026-08-10 · NCT07668388See eligibility →

Recruiting nowPhase 2

Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes

Type 1 Diabetes MellitusCondition

Tirzepatide 2.5mg weekly, Placebo injection (normal saline)Treatment

Australia1 locations

Victor Chang Cardiac Research InstituteSponsor

Updated 2026-08-10 · NCT06820281See eligibility →

Recruiting nowPhase 3

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China92 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT07571109See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Obesity, Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil61 locations

AmgenSponsor

Updated 2026-08-04 · NCT07225686See eligibility →

Recruiting nowPhase 2

Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

Obesity, OverweightCondition

KAI-7535, PlaceboTreatment

Australia, United States36 locations

KaileraSponsor

Updated 2026-07-28 · NCT07497880See eligibility →

Recruiting nowPhase 1

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZT003 Injection Following Single and Multiple Subcutaneous Administration in Healthy Volunteers/Overweight or Obese Volunteers

HealthyCondition

ZT003 - Part1 (Single ascending dose ), ZT003 - Part 2(Multiple ascending dose )Treatment

Australia2 locations

Beijing QL Biopharmaceutical Co.,LtdSponsor

Updated 2026-07-27 · NCT07184502See eligibility →

Recruiting nowPhase 3

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

Type 2 Diabetes MellitusCondition

Elecoglipron, SemaglutideTreatment

Argentina, Australia201 locations

AstraZenecaSponsor

Updated 2026-07-14 · NCT07662213See eligibility →

Recruiting nowPhase 3

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China80 locations

Novo Nordisk A/SSponsor

Updated 2026-07-13 · NCT07571005See eligibility →

Recruiting nowPhase 3

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

Weight ManagementCondition

Elecoglipron, PlaceboTreatment

Argentina, Australia321 locations

AstraZenecaSponsor

Updated 2026-07-10 · NCT07667803See eligibility →

Recruiting nowPhase 3

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Obesity, Knee Osteoarthritis (OA)Condition

NNC0487-0111, Placebo (matched to NNC0487-0111 )Treatment

Australia, Bulgaria82 locations

Novo Nordisk A/SSponsor

Updated 2026-07-09 · NCT07481630See eligibility →

Recruiting nowPhase 3

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

ObesityCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Argentina, Australia72 locations

Novo Nordisk A/SSponsor

Updated 2026-07-09 · NCT07339423See eligibility →

Recruiting nowPhase 1, Phase 2

A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus

Obesity, Diabetes Mellitus, Type 2Condition

ARO-ALK7, PlaceboTreatment

Australia, New Zealand8 locations

Arrowhead PharmaceuticalsSponsor

Updated 2026-07-08 · NCT06937203See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection FractionCondition

Maridebart cafraglutide, PlaceboTreatment

Argentina, Australia628 locations

AmgenSponsor

Updated 2026-07-02 · NCT07037459See eligibility →

Recruiting nowPhase 1

A Phase 1, Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISM8969

Healthy Subjects (HS), Obese Adult Participants at Risk of Cardiovascular DiseaseCondition

ISM8969 tablets or placebo, ISM8969 tablets or placeboTreatment

Australia1 locations

InSilico Medicine Hong Kong LimitedSponsor

Updated 2026-06-22 · NCT07581431See eligibility →

Recruiting nowPhase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults

Overweight , ObesityCondition

IBIO-600, PlaceboTreatment

Australia1 locations

iBio, Inc.Sponsor

Updated 2026-05-29 · NCT07487376See eligibility →

Recruiting nowPhase 1

An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.

ObesityCondition

RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity, PG-102Treatment

Australia1 locations

RANI TherapeuticsSponsor

Updated 2026-04-14 · NCT06891287See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

Chronic Kidney DiseaseCondition

NNC0519-0130, PlaceboTreatment

Argentina, Australia147 locations

Novo Nordisk A/SSponsor

Updated 2026-03-11 · NCT06717698See eligibility →

Recruiting nowPhase 1

A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healthy Overweight/Obese Participants

Overweight and ObesityCondition

LAE103 injection, LAE102 injection in combined with LAE103 injectionTreatment

Australia1 locations

Laekna LimitedSponsor

Updated 2026-01-20 · NCT07230496See eligibility →

Recruiting nowPhase 2

The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity（SPARKLE）

Obesity and OverweightCondition

Efsubaglutide Alfa 20 mg QW, Efsubaglutide Alfa 40 mg QWTreatment

Australia5 locations

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.Sponsor

Updated 2025-12-02 · NCT07114419See eligibility →

Recruiting nowPhase 1, Phase 2

Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity

Obesity &Amp; OverweightCondition

RN3161, Placebo ControlTreatment

Australia1 locations

Ikaria Bioscience Pty LtdSponsor

Updated 2025-11-24 · NCT07245771See eligibility →

Recruiting nowPhase 1

A Study to Evaluate MWN109 Tablets in Healthy Adult Participants

Overweight or ObesityCondition

MWN109 tablet, PlaceboTreatment

Australia2 locations

Shanghai Minwei Biotechnology Co., LtdSponsor

Updated 2025-11-20 · NCT06938269See eligibility →

Recruiting nowPhase 2

Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes

Type 2 Diabetes Mellitus (T2DM), Food EffectCondition

MKP10241, PlaceboTreatment

Australia1 locations

Mankind Pharma LimitedSponsor

Updated 2025-09-29 · NCT07098663See eligibility →

Recruiting nowNot applicable

Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents

Mental Health, Child WellbeingCondition

Intervention not listedTreatment

Australia1 locations

Murdoch Childrens Research InstituteSponsor

Updated 2025-08-03 · NCT05394363See eligibility →

Recruiting nowNot applicable

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Rare Disorders, Undiagnosed DisordersCondition

Intervention not listedTreatment

Australia, United States2 locations

Sanford HealthSponsor

Updated 2025-05-29 · NCT01793168See eligibility →

Recruiting nowPhase 4

Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)

Obesity, Knee OsteoarthritisCondition

Tirzepatide, PlaceboTreatment

Australia4 locations

University of MelbourneSponsor

Updated 2025-04-30 · NCT06191848See eligibility →

Recruiting nowPhase 1

A Study to Evaluate MWN109 Injection in Healthy Subjects

Overweight or ObeseCondition

Placebo, Subcutaneous single and mutiple doseTreatment

Australia1 locations

Shanghai Minwei Biotechnology Co., LtdSponsor

Updated 2025-04-15 · NCT06859853See eligibility →

Recruiting nowNot applicable

The Bariatric Surgery Registry

ObesityCondition

Intervention not listedTreatment

Australia1 locations

Monash UniversitySponsor

Updated 2024-12-12 · NCT03441451See eligibility →

Opening soonPhase 3

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Obesity or Overweight, Diabetes Mellitus, Type 2Condition

AZD6234, PlaceboTreatment

Argentina, Australia218 locations

AstraZenecaSponsor

Updated 2026-08-25 · NCT07784270See eligibility →

Opening soonPhase 1

A Study of SYH2092 Injection in Healthy Participants

Overweight or ObesityCondition

SYH2092 Injection, PlaceboTreatment

Australia1 locations

CSPC Megalith Biopharmaceutical Co.,Ltd.Sponsor

Updated 2026-08-20 · NCT07776041See eligibility →

Opening soonPhase 1

A Phase 1, Double-blind, Randomized Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Single Dose and Multiple Doses of CG-0416 in Healthy Participants.

Overweight and ObesityCondition

CG-0416Treatment

Australia1 locations

HongKong Curegene Innovation Co., LimitedSponsor

Updated 2026-07-24 · NCT07724431See eligibility →

Opening soonPhase 2

TriGlytza®-01 Versus Metformin in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy

Type 2 Diabetes (T2DM)Condition

Metformin XR, CelecoxibTreatment

Australia3 locations

Myopharm LimitedSponsor

Updated 2026-07-08 · NCT07139405See eligibility →

Opening soonPhase 1

Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects

Solid Tumor, ObesityCondition

SCB0020160, PlaceboTreatment

Australia1 locations

SCBIO Inc.Sponsor

Updated 2026-07-02 · NCT07682337See eligibility →

Opening soonPhase 2

Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

Methamphetamine Use DisorderCondition

12 weeks of weekly subcutaneous semaglutide injectionTreatment

Australia5 locations

Kirby InstituteSponsor

Updated 2026-06-26 · NCT07509112See eligibility →

This page shows the first 60 studies. Use the full search to filter all matches.

Related countries

United States1,107 China326 Canada158 France110 Spain98 Germany95

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.